Evidence map›Paper›PMID 40093303›Full record

ArticleBioactive materials2025

A micro-metabolic rewiring assay for assessing hypoxia-associated cancer metabolic heterogeneity.

Jeong Min Oh, Tianze Guo, Hydari Masuma Begum, Saci-Elodie Marty, Liang Sha, Cem Kilic, Hao Zhou, Yali Dou, Keyue Shen

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bioactive materials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Jeong Min OhDepartment of Biomedical Engineering, University of Southern California, Los Angeles, CA, 90089, USA.
Tianze GuoDepartment of Biomedical Engineering, University of Southern California, Los Angeles, CA, 90089, USA.
Hydari Masuma BegumDepartment of Biomedical Engineering, University of Southern California, Los Angeles, CA, 90089, USA.
Saci-Elodie MartyDepartment of Biomedical Engineering, University of Southern California, Los Angeles, CA, 90089, USA.
Liang ShaDepartment of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, 90033, USA.
Cem KilicDepartment of Biomedical Engineering, University of Southern California, Los Angeles, CA, 90089, USA.
Hao ZhouDepartment of Biomedical Engineering, University of Southern California, Los Angeles, CA, 90089, USA.
Yali DouDepartment of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, 90033, USA.
Keyue ShenDepartment of Biomedical Engineering, University of Southern California, Los Angeles, CA, 90089, USA.

Funding

USC/NORRIS COMPREHENSIVE CANCER CENTER (CORE) SUPPORTP30CA014089 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI VERONICA WENDY SETIAWAN · 1985 to 2026
$181.4M
(PQ5) Microenvironmental Regulation of Mitochondrial Heterogeneity in Cancer MetastasisR01CA220012 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI SHEN, KEYUE · 2019 to 2023
$2.2M
Non-canonical function of transcription cofactor MLL1 in cancerR01CA287625 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Yali Dou · 2024 to 2026
$1.5M
NCI NIH HHS P30 CA014089NCI NIH HHS R01 CA220012NCI NIH HHS R01 CA287625
6 · The paper itself

Abstract

Cancer metabolism plays an essential role in therapeutic resistance, where significant inter- and intra-tumoral heterogeneity exists. Hypoxia is a prominent driver of metabolic rewiring behaviors and drug responses. Recapitulating the hypoxic landscape in the tumor microenvironment thus offers unique insights into heterogeneity in metabolic rewiring and therapeutic responses, to inform better treatment strategies. There remains a lack of scalable tools that can readily interface with imaging platforms and resolve the heterogeneous behaviors in hypoxia-associated metabolic rewiring. Here we present a micro-metabolic rewiring (μMeRe) assay that provides the scalability and resolution needed to characterize the metabolic rewiring behaviors of different cancer cells in the context of hypoxic solid tumors. Our assay generates hypoxia through cellular metabolism without external gas controls, enabling the characterization of cell-specific intrinsic ability to drive hypoxia and undergo metabolic rewiring. We further developed quantitative metrics that measure the metabolic plasticity through phenotypes and gene expression. As a proof-of-concept, we evaluated the efficacy of a metabolism-targeting strategy in mitigating hypoxia- and metabolic rewiring-induced chemotherapeutic resistance. Our study and the scalable platform thus lay the foundation for designing more effective cancer treatments tailored toward specific metabolic rewiring behaviors.

Indexed as

HypoxiaMetabolic rewiringMetabolism-targeting therapyTumor heterogeneityTumor microenvironment

Identifiers

PMID40093303
PMCPMC11910375

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.